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Abstract
Our understanding of the basis of severe disease in malaria is incomplete. It is clear that pathology is in part related to the
pro-inflammatory nature of the host response but a number of other factors are also thought to be involved, including the
interaction between infected erythrocytes and endothelium. This is a complex system involving several host receptors and a
major parasite-derived variant antigen (PfEMP1) expressed on the surface of the infected erythrocyte membrane. Previous
studies have suggested a role for ICAM-1 in the pathology of cerebral malaria, although these have been inconclusive. In
this study we have examined the cytoadherence patterns of 101 patient isolates from varying clinical syndromes to CD36
and ICAM-1, and have used variant ICAM-1 proteins to further characterise this adhesive phenotype. Our results show that
increased binding to CD36 is associated with uncomplicated malaria while ICAM-1 adhesion is raised in parasites from
cerebral malaria cases.
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Introduction
Infections by the human malaria parasite Plasmodium falciparum can
lead to a range of severe outcomes including severe anaemia, organ
failure, coma and eventually death. The sequestration of P. falciparum
infected erythrocytes deep in micro-vasculature is implicated in
malaria pathology [1–3]. To date 11 host receptors have been
identified that mediate adhesion to endothelium including CD36 and
ICAM-1 to which most clinical P. falciparum isolates adhere [4].
Binding to the endothelial receptor ICAM-1 has been associated with
sequestration in brain vasculature [5] and showed a weak but not
statistically significant association in one study with cerebral malaria
(CM), while adhesion to CD36 showed no association [6]. Other
adhesive phenotypes such as formation of rosettes [7–9] and the
ability to bind receptors expressed on the placenta [10–12] have
consistently shown strong associations with pathology. The parasite
ligand responsible for binding, PfEMP1 (transcribed from the var gene
family), contains motifs responsible for adhesion (Duffy Binding Like
domains and cystein-rich interdomain regions [13–20] to a range of
host receptors including ICAM-1 [21]; CD36[22,23] P-Selectin [24];
PECAM/CD31 [25]; CR1 [13]. As demonstrated in the field of
pregnancy associated malaria, characterizing the molecular nature of
these interactions is important in understanding the pathogenesis of
the more severe forms of malaria, because it would potentially
provide more information in the design of new methods of prevention
and treatment [10,26–29].
Intercellular adhesion molecule 1 (ICAM-1) is a 90–115 kDa
transmembrane glycoprotein expressed on a variety of cell types
including endothelial cells [30]. Its expression in vivo is upregulated
in response to a variety of inflammatory mediators including
tumour necrosis factor (TNF) and interleukin-1 (IL-1). ICAM-1 is
of interest because its expression on brain endothelium is up-
regulated in severe malaria [1] and a natural polymorphism
termed ICAM-1Kilifi affects disease severity in some parts of Africa
[31,32]. This mutation involves a lysine to methionine substitution
at position 29 and is present at a gene frequency of 30% in African
populations [31–33]. Binding to ICAM-1 is not a simple
phenotype and a number of laboratory-adapted parasite lines
such as A4u, ItG, C24 and JDP8, show varying binding
phenotypes under flow or static conditions. Tse and others in
2004, targeted amino acid residues within the ICAM-1 protein
and introduced alanine mutations that resulted in 25 mutant
proteins, including ICAM-1S22/A, in which serine at position 22 is
replaced by alanine. This and earlier studies [34,35] revealed that
A4u and ItG demonstrated differential binding abilities to ICAM-
1Reference, ICAM-1Kilifi and ICAM-1S22/A. The laboratory line
A4u binds moderately to ICAM-1 [36] with little stationary
adhesion under flow whereas the main adhesive interactions were
of the rolling type. ItG and JDP8 showed stronger stationary
binding but significantly lower rolling under these conditions [34–
37]. The laboratory line C24 on the other hand does not bind to
ICAM-1. A4u, ItG and C24 bound to CD36 while JDP8 showed
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significantly lower adhesion to this receptor. These variations in
binding may be explained by the differential adhesion properties
of the variant surface proteins (PfEMP1) expressed by each
parasite line or the expression levels of PfEMP1.
CD36 is an 88 kDa integral membrane protein found on
various host cells including endothelium, monocytes and platelets.
This receptor has multiple functions that include platelet adhesion,
non-opsonic phagocytic clearance of senescent or pathologically
altered cellular structures by pattern recognition [38] and
regulation of different metabolic pathways, membrane transport
systems and immune responses in humans [39,40]. Almost all P.
falciparum paediatric clinical isolates adhere to CD36 and no
difference in CD36-binding of parasites from severe or uncompli-
cated parasites has been observed [6,41]. However, a recent paper
has suggested that CD36 deficiency may protect against falciparum
malarial anaemia [42] and pregnancy-associated P. falciparum
isolates were found not to bind to CD36 [10,43].
Adhesion of P. falciparum laboratory lines or clinical isolates has
been assessed using two techniques, namely static and laminar flow
adhesion assays. The former measures immobilization of parasit-
ized cells on proteins, while the latter attempts to mimic the
physiological system allowing for measurements of the strength or
avidity of the interaction between infected cells and endothelial
receptors [44,45]. The majority of adhesion studies conducted so
far have concentrated on adhesion of clinical isolates under static
conditions, while here we consider the effect of flow and static
conditions in parallel to give different information about ligand-
receptor interactions. For example studies under static conditions,
using ItG and JDP8 revealed that these parasites are high avidity
ICAM-1 binders, when presented on TNF-activated HUVEC
[36], but under laminar flow these parasites bound poorly. A4u
showed the opposite effect to that observed with ItG and JDP8 and
bound strongly under flow conditions. Our intention in using both
types of assays for ICAM-1 binding is to take into account previous
work with this receptor indicating that its role in adhesion is
particularly associated with recruitment from flow [45].
Genetic polymorphisms of affected populations and the presence
of specific falciparum gentoypes can both modulate the impact of
falciparum malaria infections in endemic areas. Mutations in the
human genes ICAM-1, CD36 and globin genes have been
associated with susceptibility to severe falciparum malaria [46–48],
in some but not all populations. For example, the homozygous
ICAM-1Kilifi has previously been shown to be associated with
cerebral malaria in Kenya, while in Malawi, children with the same
phenotype showed increased mortality (Turner, unpublished
observations). Other studies in West Africa did not show any
association [33] and a more recent study in Kilifi suggested that the
effect of the ICAM-1Kilifi mutation is probably more important in
infections other than malaria [48]. In addition, children homo-
zyogous for a mutation change of T to G in the CD36 gene at
nucleotide position 188 in exon 10 [49] are protected against severe
malarial anaemia and children carrying the sickle cell trait, HbS are
protected against all forms of malaria disease [42,46,47,50–52].
We have analysed the role of polymorphic variants of ICAM-1
in severe falciparum malaria using static and flow based adhesion
assays and CD36 in static assays only. Understanding the adhesion
mechanisms of parasites will provide us with a better understand-
ing of disease progression.
Materials and Methods
Ethics Statement
The proposal for this study was reviewed and passed as ethically
acceptable by the Kenya Medical Research Institute and National
Ethic Review Board and the Oxford Tropical Medicine Research
Ethics Committee (OXTREC). In addition, a fully informed
written consent was obtained from parents/legal guardians of
every child enrolled in the study.
Collection and culture of P. falciparum clinical isolates
Parasite samples were collected between 2005 and 2009 from
children attending Kilifi District Hospital, Kenya who had a
primary diagnosis of P. falciparum malaria and from a cohort of
children under active surveillance for acute malaria in the Junju
area of Kilifi District in Kenya. The samples were collected before
anti-malarial treatment was administered. Only children with a
parasitaemia above 3% were included in the study as this level of
parasitaemia is required for the adhesion assays. Taking advantage
of an already established algorithm [53] that allocates a unique,
anonymous identifier for selection and processing of patient blood
samples, patients were chosen using the inclusion criteria shown
below. Sample processing, adhesion assays and data analysis were
performed using the unique identifier so that the origin and
clinical details of the sample remained unknown until the study
was completed. Children presenting with febrile illness and
peripheral P. falciparum parasitaemia were included in this study.
Severe malaria defined as hospital admissions, was further
divided into three categories namely: Cerebral Malaria (CM) with
a Blantyre Coma Score (BCS) of #2 [54,55], Severe malaria
anaemia (SMA) had a haemoglobin concentration ,5g per
deciliter, [56] and Severe malaria-other (SM-other) patients with
neither severe anaemia nor cerebral malaria (BCS.2). Lastly,
patients recruited from peripheral dispensaries with no severe
complications were termed Non-severe malaria (Uncomplicated,
UM) [55–58].
167 patient samples were entered into the study, consisting of 85
frozen and 82 fresh isolates. 66 frozen isolates failed to meet the
requirements of the adhesion assays (either through failure to grow
or insufficient material recovered for the binding assays) giving a
total of 101 isolates that were investigated for their binding to
ICAM-1 and CD36.
Culture of parasites
P. falciparum lines derived from the laboratory line IT4/25/5
[59,60], ITO4-A4u (A4u) and ItG, which have previously been
selected for binding on ICAM-1, were used as controls. To
minimize the effect of antigenic switching in culture, a batch of
stabilates, selected on a variant specific monoclonal antibody BC6
(A4u) and by repeated selection on ICAM-1 (ItG) were serially
thawed and maintained in culture for not more than three weeks.
Parasites were prepared as previously described [58] from acute
samples. In brief, RBCs were purified from mononuclear cells and
granulocytes using lymphoprep and Plasmion, respectively.
Parasites were grown to maturity for 24 to 48 hours either from
frozen (n = 19) or fresh (n = 82) isolates.
Laboratory parasite lines and parasites from patient isolates
were cultured from pre-treatment blood samples at 2% hematocrit
in O+ human erythrocytes using standard culturing techniques,
[61] using RPMI 1640 medium (supplemented with 37.5 mM
HEPES, 7 mM D-glucose, 6 mM NaOH, 25 mg of gentamicin
sulfate/ml, 2 mM L-glutamine, and 10% human serum) at a pH
of 7.2 in a gas mixture of 96% nitrogen, 3% carbon dioxide, and
1% oxygen. The parasite density was calculated by determination
of the number of parasites per 200 white blood cells (WBC) for
thick blood film or 500 red blood cells (RBC) for thin blood films.
Baseline WBC or RBC counts were used to calculate the
parasitaemia (parasites/ml). For all adhesion assays the parasitae-
Malaria, ICAM-1, CD36, Adhesion
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mia was adjusted to 3% and 1% hematocrit (approximately 30000
parasites/ml, based on an estimation of 109 RBCs/100ml).
Recombinant proteins
Purified receptors used in this study were CD36 (R & D
Systems, UK), ICAM-1-Fc reference (the wild type allele of
ICAM-1 (ICAM-1Reference)) [37], ICAM-1 Kilifi (ICAM-1Kilifi)
[16,38] and ICAM-1 S22/A (ICAM-1S22/A) [62].
Static adhesion assays
Purified recombinant proteins were spotted in triplicate in a
radial pattern using 2 ml spots on 60615 mm bacteriological
plastic petri dishes (Falcon 1007; Becton Dickinson, Oxford, UK)
at concentrations of 50 mg/ml for ICAM-1 and CD36 proteins.
These concentrations had previously been shown to be within the
dynamic range for detecting differences in adhesion and produce
coated surfaces with receptors at levels approximately equal to
receptor densities seen on activated endothelium or basal levels of
CD36 [36]. The dishes were placed in a humidified chamber for
2hrs at 37uC to allow the proteins to adsorb to the surface, after
which the protein solutions were aspirated off and the uncoated
plastic area blocked overnight with 1% BSA/PBS at 4uC. The
plates were warmed at 37uC for one hour, blocking solution (1%
BSA/PBS) removed and washed twice in binding buffer (RPMI
1640 in 2% glucose) prior to adding 1.25 ml of parasite cultures at
3% parasitaemia, which had been washed twice in binding buffer
and resuspended to 1% haematocrit. The plates were incubated at
37uC for one hour with gentle resuspension every 10 minutes.
Unbound infected and uninfected erythrocytes were removed by
gentle manual washing (4–6 washes) with 1.5 ml binding medium
(monitoring of adhered cells was performed using an inverted
microscope). The adhered infected erythrocytes were fixed with
1% glutaraldehyde in phosphate buffered saline for 1 hour and
stained with 10% giemsa for 15 minutes. Adhesion levels were
quantified by microscopy using the unique, anonymous identifier
(with the operator blinded to the clinical category) and results were
expressed as the mean number of parasitized erythrocytes bound
per mm2 of surface area.
Flow adhesion assays
Using a modified method [36,44] microslides (Camlab, UK)
were coated with ICAM-1 recombinant proteins at 50 mg/ml at
4uC overnight followed by blocking with 1% BSA/PBS at 37uC
for two hours. Microslides were connected to tubing mounted on a
microscope stage (Nikon; Eclipse TE 200) enclosed within a plastic
chamber that maintains the temperature at 37uC. Tubing was
mounted to a system that allows medium to flow through at a
controlled rate of 186 ml/minute (0.05 Pa). Infected erythrocyte
suspensions were passed over the slide for a total of 6 minutes
followed by buffer flowed to remove any unbound cells (2
minutes). This flow rate mimics the flow rate in the micro-
vasculature.
At the end of each 8 minute run, the total number of stationary
infected erythrocytes was counted in six separate fields on each
microslide with the buffer still running. Using one protein per
microslide, all controls and clinical samples were run in duplicate
in a single experiment.
Patient and parasite genotypes
CD36, ICAM-1, a-thalassemia and sickle cell genotypes were
determined in all patients using allele-specific polymerase chain
reaction described elsewhere [31,33,49,63,64]. To determine the
extent of mixed parasite populations a multi-plexed fluorescent
labeling system for genotyping MSP1 (subfamilies MAD20, K1,
RO33) and MSP2 (subfamilies FC27 and IC) was used [65].
Binding signatures for P. falciparum clinical isolates under
static conditions
The larger dataset for static assays was available for further
analysis of the ICAM-1-binding phenotype. The binding data of
clinical isolates was converted into binding signatures by
comparing their ICAM-1Kilifi and ICAM-1S22/A adhesion against
that of ICAM-1Reference as the reference standard. This allowed us
to subtype these isolates for ICAM-1 adhesion using a two-letter
code based on relative binding to Kilifi and S22/A proteins
respectively. The absolute binding values obtained were converted
into percentage values relative to ICAM-1Reference binding and
designated high binders 80–100% (binding signature ‘a’), moder-
ate binders 50–79% (binding signature ‘b’) and low binders 0–49%
(binding signature ‘c’) (see Table S1).
Data Analysis
Statistical analysis was carried out using STATA (version 9.0)
and Prism (version 5.0). Distributions were frequently highly
skewed from normal so non-parametric tests of significance (e.g.
Mann-Whitney) were applied.
Results
Study Population
From a total of 167 blood samples screened for parasite growth
and recovery only 101 were used for adhesion studies. Previous
studies used frozen ring stage parasites for adhesion assays [6], but
in our study, these frequently failed to grow or did not achieve the
required parasitaemia of $30,000/ml required for accurate
assessment of binding to different ICAM-1 variants (Figure 1).
In addition, other studies [41,66], including some recently
published data [67], have suggested that significant phenotypic
changes in var expression may take place on freezing and thawing
particularly if parasite cultures are grown in vitro for 5–6 cycles.
Isolates in this study were grown for a single cycle and because
most frozen isolates failed to grow (only 19 out of a total of 66
attempted) we resorted to using fresh isolates (n = 82), to give a
total of 101 isolates that were analysed for adhesion (Figure 1). The
growth characteristics for isolates from both UM and severe
malaria cases were similar.
Out of the 101 children, 45 had uncomplicated malaria, while
56 had severe malaria. Children with severe disease (SMA, CM
and severe malaria-other) had a median age of 4 years
(interquartile range 3–6 years) and those with uncomplicated
malaria had a median age of 5 years (interquartile range 4–6
years). All children were free of other secondary infections and
were split into different clinical groups as shown in Table 1. We
observed that children with severe malaria-other had a high
median parasitaemia of 582120 parasites/ml (interquartile range
194140–739405), followed by children with CM (median 457420,
interquartile range 230880–630450) and those with SMA and
uncomplicated malaria had a lower median parasitaemia of
228000 and 235000, respectively (Table 1). The parasites that
grew to trophozoite stage were assessed for adhesion under static
and flow conditions, although in some cases the sample volume
was limited and static adhesion alone was carried out (Figure 1).
Cases of SMA were infrequent in this population (n = 8) and only
one patient had both cerebral malaria and a haemoglobin (Hb) of
less than 5 g/dl. This patient was considered in both the CM and
SMA arm.
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Effect of clinical syndromes on adhesion
In this study, we observed that 80% of clinical isolates bound to
both CD36 and ICAM-1 (Table S2). As with previous findings [6],
children with an Hb of ,5 g/dl showed reduced adhesion under
static conditions (Figure 2a). For static conditions, we have shown
significantly higher binding to CD36 by UM isolates [mean
adhesion 1177.2 parasites/mm2 (95% confidence interval (CI),
829.0–1525.3)] compared to CM isolates [mean adhesion 502.3
parasites/mm2 (95% CI, 179.6–825.0) (p = 0.016, Mann-Whitney
test)] and SMA isolates [mean adhesion 158.5 (95% CI -38.4–
355.4) (p = 0.006, Mann-Whitney test)] . Intermediate significance
was observed when UM cases were compared to children with
SM-other [mean adhesion 645.0 (95%CI, 370.6–919.4)] to CD36
under static conditions (p = 0.050, Mann-Whitney test). Children
below one year admitted with severe disease, irrespective of the
clinical syndrome, showed reduced levels of adhesion to all three
ICAM-1 protein variants and CD36 under static and flow
conditions, but numbers were too few (n = 8) to test for
significance.
We did not observe differences in binding densities to ICAM-1
protein variants under stationary adhesion conditions. Under
flow conditions, however, CM cases (accounting for 30% of total
number of children recruited) showed the highest adhesion under
flow conditions. Mean adhesion under flow to ICAM-1Reference
for CM was 158.0 parasites/mm2 (95% CI, 63.6–252.4), for
SMA 52.8 parasites/mm2 (95% CI, 28.7–114.3), SM-other 42.8
parasites/mm2 (95% CI, 13.0–72.6) and UM 48.7 parasites/
mm2 (95% CI, 21.9–75.5) (Figure 2b). Binding densities to
ICAM-1Reference were significantly higher for CM isolates than
for isolates from children with UM or SM-other (Figure 2b),
under flow conditions (p = 0.009 and 0.012 respectively, Mann-
Whitney).
Table 1. Clinical samples included in the study and classified into different severity groups.
Severity group Clinical status n Parasite count (per/ml) Median age (yr)
Severe anaemia Q Hb,5 g/dl 8 228000 (166870–255900) 2.5 (1.8–3.3)
Cerebral malariaQ BCS#2, prostrated unconscious 19 457420 (230880–630450) 3 (2–4)
Severe malaria-other* BCS.2 30 582120 (194140–739405) 3 (2–5)
Uncomplicated malaria Mild disease, no severe
complications
45 235000 (136300–385400) 5 (4–6)
Numbers in parentheses represent the interquartile ranges.
*Severe malaria-other-severely ill children who did not meet the criteria for severe anemia or cerebral malaria.
Q 1 patient had both CM and anaemia.
doi:10.1371/journal.pone.0014741.t001
Figure 1. Distribution of clinical samples used in the study. Scheme showing the collection and classification of infected blood samples from
children with different malaria syndromes: uncomplicated (UM), severe malaria other (SM other); cerebral malaria (CM); severe malaria anaemia (SMA).
The following symbols designate: * severe malaria but no CM or anaemia; Q one patient had an Hb,5g/dl and CM; n = number of clinical samples;
low para, low parasitaemia
doi:10.1371/journal.pone.0014741.g001
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Association of host or parasite genotypes with adhesion
There was no significant difference in the mean cytoadherence
values or clinical syndromes between isolates from patients with
different a-Thalassemia, ICAM-1, CD36 genotypes and HbS, sickle
cell genotypes (Table S3) or between patients with isolates with
different MSP1/ MSP2 genotypes or numbers of circulating
genotypes. The majority of children had 2 circulating parasite
genotypes and the mean number of parasite genotypes was greatest
in CM cases and lowest in UM cases, although these differences
were not statistically significant (Table 2). Among the 101 patients
screened, we found that all were HbAA (normal haemoglobin)
except for three UM cases that were HbAS, sickle trait carriers.
Analysis of ICAM-1 binding signatures
Since a weak association between ICAM-1 binding and
pathology has been suggested by previous work, further analysis
of the binding phenotypes of clinical isolates for adhesion to
ICAM-1 variant proteins was performed to develop a more
detailed picture of the nature of this interaction (Figure 3 and
Table S1). Clinical isolates were found to exhibit differential
binding densities to the three ICAM-1 protein variants Reference,
Kilifi and S22/A. This allowed us to sub-type the binding to
ICAM-1 into different categories, for example, A4u binds weakly
to ICAM-1Kilifi and strongly to ICAM-1S22/A and when these were
compared against ICAM-1Reference it gives a ‘ca’ type (c = low
binding; a = strong binding). ItG on the other hand, gives a ‘bc’
type (b = moderate binding to Kilifi and c = low binding to S22/A
when compared to Reference). Similarly clinical isolates display
varying binding signatures when ICAM-1Reference is taken as the
reference point (Table S1). Data analysis was performed using
static data only. The number of isolates in Severe Malaria-other
were n = 22, CM n = 13 and UM n = 32. Isolates that gave no
adhesion to ICAM-1 proteins were excluded from this analysis. Of
the nine ICAM-1 binding signatures defined by this approach,
only the ‘‘ca’’ type was more frequent among the severe malaria
isolates than among the UM isolates, but this was not statistically
significant (Odds Ratio 7.750 (95%CI 0.896–67.02) p = 0.056,
two-tailed Fishers exact).
Figure 2. Mean adhesion of clinical isolates to CD36 and ICAM-1 proteins. Experiments were performed under static (a) and flow (b)
conditions at coating concentrations for CD36 and ICAM-1 proteins of 50 mg/ml. Data represent the mean number of adherent parasites per
mm26standard error. p values that describe significant associations are shown.
doi:10.1371/journal.pone.0014741.g002
Table 2. Association of clinical syndromes with MSP1 and MSP2 parasite genotypes.
Alleles CM SMA SM-O UM
MSP1 MAD20 14.5 15.4 10.6 9.5
K1 27.1 15.4 31.8 28.6
RO33 10.4 23.1 7.6 23.8
MSP2 FC27 16.7 15.4 24.2 23.8
IC 31.3 30.8 25.8 14.2
Mean no. of
genotypes (95% CI)
2.9 (2.5–3.2) 2.2 (1.5–2.8) 2.6 (2.1–3.0) 2.6 (1.5–3.7)
Data is presented as a % of respective genotypes in each clinical category.
CM, cerebral malaria; SMA, severe malarial anemia; UM, uncomplicated malaria; SM-O, severe malaria-other-severely ill children who did not meet the criteria for severe
anemia, cerebral malaria.
doi:10.1371/journal.pone.0014741.t002
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Discussion
This current study assessed the adhesion of P. falciparum infected
erythrocytes under flow (ICAM-1) and static (ICAM-1 and CD36)
conditions from children with different clinical syndromes of
malaria. P. falciparum isolates from children with UM have
significantly higher levels of adhesion to CD36, under static
conditions, than isolates from children with severe disease (CM,
Severe Malaria-other and SMA). Previous studies had revealed
that almost all isolates of P. falciparum adhere to CD36 [2,42,68,69]
and in Africa no differences in CD36-binding ability between SM
and UM cases were observed [6,25,41,70], although one study in
Mali showed a positive association with a sub-type of PfEMP1
(cys2var) and severe malaria and this var type is part of a group of
PfEMP1 proteins that tend to have lower binding to CD36 [71].
In adults in South East Asia, higher CD36 binding (using C32
cells) was observed among P. falciparum isolates from patients with
severe (but not cerebral) malaria [72]. Most of these earlier studies
used frozen parasite isolates and the sample sizes were relatively
small. In our study, freshly grown parasite isolates have given some
different patterns of association between binding and clinical
phenotypes than the frozen ones used in the Newbold et al paper
[6], although we did not have an asymptomatic group which was
present in this latter study so care needs to be taken in making this
comparison.
One potential weakness of this study is that bias may have been
introduced by only analyzing parasites isolates with an in vivo
parasitaemia that exceeds 30000/ml, but for adhesion based
studies such parasitaemias are required to obtain accurate
measurements. It is possible that this cut off may have resulted
in the exclusion of SMA cases which often have parasitaemia
below 30000/ml [73,74]. However this parasitaemia may also be
an advantage in that the UM controls will be from patients with
relatively high parasitaemia and so better matched to the CM
isolates. A second potential weakness is that adhesion to CD36 was
not studied under laminar flow conditions as sample volumes were
limiting, reducing the number of analyses possible. Data relating to
var types of patients is not currently available but this work is in
progress and forms part of a large study examining many factors of
parasite biology (P. Bull, personal communication). This informa-
tion once available may explain why we observed reduced
adhesion in children below one year of age, based on the subset
of PfEMP1 proteins observed in this category.
CD36 receptor is involved in non-opsonic phagocytosis of
parasite infected erythrocytes by monocytes and macrophages
[38,75,76] and in the uptake of antigens into dendritic cells, (DCs)
[77,78]. Binding of infected erythrocytes to DCs modulates their
maturation in vitro [76] leading to upregulation of IL-10 and
down regulation of IL-12. This may in turn limit the production of
inflammatory responses that are associated with severe clinical
outcomes. The high levels of adhesion of UM cases to CD36
observed in this study suggest a role of this receptor in host control
of parasitaemia, before antigen-specific immune responses occur
and/or limitation of pro-inflammatory responses. This hypothesis
is in contrast to the common view of CD36 as a receptor exploited
by the parasite for the purpose of tissue sequestration.
The pathogenesis of severe falciparum malarial anaemia arises
due to decreased production and increased destruction of
erythrocytes [79,80]. Unlike high malaria transmission areas
where severe malaria anaemia cases are common [81,82], the
incidence of SMA has fallen dramatically in Kilifi district over the
last ten years [83]. The reduction in adhesion observed in the
SMA group was not due to the presence of polymorphisms such as
sickle cell, a-thalassemia or CD36-deficiency as previously shown
by other groups [42,51,84]. A modification in the surface
membrane of erythrocytes leading to alterations in expression of
surface host receptors CR1, CD55 and CD59 has previously been
shown to occur in erythrocytes from SMA children [85], whether
this affects PfEMP1 display remains to be determined but this
could explain why isolates from these patients show reduced
adhesion [30]. Furthermore, four SMA out of the eight were
microcytic with a mean corpuscular volume (MCV) below normal
range (data not shown) and one of these patients had respiratory
distress. Despite MCV being below normal range, this did not
explain reduced adhesion as values varied when compared
between patients independent of MCV. It is also possible that
SMA may lead to the selection of particular PfEMP1 variants, as
seen in children with Hb-S and Hb-C, which could affect their
adhesion characteristics (Fairhurst, pers. comm.). Further studies
are needed to understand the molecular basis of this phenomenon.
Detectable binding of P. falciparum clinical isolates to ICAM-1
had previously been shown to have a prevalence of 80% in this
population [6] and our study found similar levels (Table S2).
Newbold and others [6] did not observe a significant association
with CM but with malaria disease (CM and UM combined) when
compared with asymptomatic infection. We found that binding to
ICAM-1Reference is associated with CM, and levels of binding of
isolates from patients with this clinical syndrome were found to be
significantly higher than UM cases when using flow-based assays.
Under flow, but not static conditions, ICAM-1 captures infected
erythrocytes, suggesting that this process of capturing from flow is
a critical one in the pathogenesis of CM. This is in agreement with
previous findings that in some laboratory isolates ICAM-1 is
important for efficient adhesion to HUVEC [36] and suggests a
mechanism for severe disease based on preferential recruitment of
specific adhesive types of parasites in the circulation to brain
endothelium. This would also fit with other work, which showed
that the adhesion of different parasite variants was not evenly
distributed among tissues, but instead that accumulation of
Figure 3. Binding signatures for P. falciparum clinical isolates
under static conditions. Binding signatures calculated by comparing
ICAM-1Kilifi and ICAM-1S22/A clinical binding data against that of ICAM-
1Reference the reference standard. Data was calculated using adhesion to
ICAM-1Reference as a standard against which relative adhesion to ICAM-1
Kilifi and S22/A are calculated. a, designates strong (80–100%), b,
moderate (50–79%) and c, low (0–49%) adhesion. The number of
isolates with Severe malaria n = 35 and UM n=32.
doi:10.1371/journal.pone.0014741.g003
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parasites expressing particular var-types was organ-specific (in-
cluding brain) [86].
ICAM-1 is also an attachment molecule for the major serotypes
of human rhinovirus (HRV) that are responsible for localizing the
virus near the cellular membrane and triggering conformational
changes in the viral capsid that initiate uncoating and epithelial
cell invasion [87]. Studies on human rhinovirus (HRV) using two
different HRV serotypes have shown varying adhesion phenotypes
to ICAM-1Reference and ICAM-1Kilifi, and their association with
varying clinical outcome [88]. A similar situation may occur in P.
falciparum variants from the field as shown in this study and in
laboratory lines [63] that exhibit differential adhesion abilities to
all three ICAM-1 proteins. When we tested patient isolates for
their ability to bind to three different forms of ICAM-1 under
static conditions, we saw a broad distribution of adhesion types but
an excess of ‘ca’ type in severe malaria (CM and SM other
combined, although the majority of ‘ca’ types were in the CM
category (Table S1)). It should be noted that this association did
not reach statistical significance (p = 0.056). It is possible that this
binding signature is linked to pathogenesis, although further
studies are required to study this. The ‘ca’ binding signature is
shared with the A4 parasite variant, and the ITO4 line, which was
isolated after selection on activated human umbilical vein
endothelial cells (HUVEC). In contrast, ItG parasites selected by
binding to purified ICAM-1 protein displayed the ‘bc’ binding
signature, which was not prevalent among parasites isolated from
children with severe malaria (Figure 3). HUVEC expresses ICAM-
1 on TNF stimulation but not CD36 and is used widely as a model
of brain sequestration in vitro [21,36,59,89]. Thus a binding
signature exhibited by parasites isolated from children with severe
malaria is similar to that exhibited by a parasite line selected for
binding to endothelial cells with a receptor distribution similar to
that seen in the brain. However, another parasite line from the IT
parent line, ItG, is not associated with severe falciparum malaria
despite being selected on ICAM-1, implying that the cellular
context of the receptor may also be important. The numbers
available for this part of the study were limited and further work
will be required to confirm this observation.
The number of circulating genotypes in a given sample indicates
the extent of parasite diversity and may explain varying adhesion
phenotypes observed. This study analysed MSP1 families
(MAD20, K1, RO33) and MSP2 families (FC27, IC) to answer
this question. We did not see any associations with the number of
or type of parasite genotypes and clinical syndromes. A limited
parasite diversity as observed in a previous study [90] was seen.
Conflicting results between the allelic family present and
association with disease severity have been seen in other studies
showing MSP2/ IC type dominant in asymptomatic infections
[91,92] while others showed an association of MSP2/ FC27 with
symptomatic malaria [93]. Our study also observed the predom-
inance of the allelic family MSP1/ K1 as seen in a study in Gabon
[94]. Human genotypes like the haemoglobinopathies HbS and
HbC are known to be relevant in cytoadherence. A recent study
suggested that these polymorphisms can affect the display of
PfEMP1 and thereby reduce adhesion [52]. In our study we found
only three HbAS carriers, which was too few to draw any
conclusions. We further found no evidence of an association
between carriage of particular allelic families of msp1 or msp2 and
either severity of clinical presentation, or adhesion phenotype.
As with pregnancy-associated malaria, the aim now is to use this
information to understand the basis of severe malaria and identify
novel approaches to prevention or treatment. This will not be a
simple task (see [4] for a review of this area), due to several factors
such as severe malaria consisting of a diverse collection of
syndromes and the involvement of multiple receptors producing
synergy such as that observed between ICAM-1 and CD36.
Indeed the role of other receptors besides ICAM-1 and CD36
should not be discounted in terms of their contribution to disease,
for example, gC1qR can act as a receptor for binding to brain
microvascular endothelial cell lines [95] but its role in CM is yet to
be determined.
In summary, this study has identified significant associations
between receptor usage by pediatric clinical isolates and disease
severity. We have shown for the first time in African children that
parasites isolated from children with UM bind to CD36 at higher
densities than parasites from children with severe malaria.
Importantly, high density parasite binding to ICAM-1 under flow
conditions was significantly associated with cerebral malaria. The
findings presented here provide a platform from which to focus
efforts on blocking or reversing ICAM-1-mediated adhesion to
reduce cerebral malaria as well as a reconsideration of anti-CD36
strategies for controlling severe malaria.
Supporting Information
Table S1 Binding signatures for clinical isolates under static
conditions. Binding signatures of clinical isolates presented as %
binding and coloured codes. K29, % adhesion to ICAM-1Kilifi,
S22, % adhesion to ICAM-1S22/A and column 3, binding
signature. Binding is calculated relative to ICAM-1Reference as
reference standard. The numbers of isolates in SMA n = 5, CM
n = 13, Severe Malaria-other n = 22 and UM n = 32.
Found at: doi:10.1371/journal.pone.0014741.s001 (0.08 MB
DOC)
Table S2 Adhesion data for clinical P. falciparum isolates under
static and flow adhesion assays. Numbers represent number of
adherent parasites/mm2. (-) no data available.
Found at: doi:10.1371/journal.pone.0014741.s002 (0.14 MB
DOC)
Table S3 Genotype frequencies for ICAM-1, CD36, a-thalas-
saemia and HbS. Genotype frequencies for patients studied. HbS,
haemoglobin S variant (sickle cell genotype). CD36, point
mutation from T to G in the CD36 gene at nucleotide position
188 in exon 10. Numbers represent the number of children that
fall into each genotype (wild-type, heterozygous and homozygous).
Numbers in parenthesis is given as a percentage of respective
genotypes.
Found at: doi:10.1371/journal.pone.0014741.s003 (0.03 MB
DOC)
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